Literature DB >> 22995726

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.

Lawrence T Goodnough1, Peter K Smith2, Jerrold H Levy3, Robert S Poston4, Mary A Short5, Govinda J Weerakkody5, LeRoy A LeNarz5.   

Abstract

OBJECTIVE: Coronary artery bypass grafting-related bleeding and associated transfusion is a concern with dual antiplatelet therapy in patients with acute coronary syndromes. The objective of the present study was to characterize a potential risk-adjusted difference in transfusion requirements between prasugrel and clopidogrel cohorts.
METHODS: The data from 422 patients undergoing isolated coronary artery bypass grafting from the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 were analyzed retrospectively.
RESULTS: We found no difference in baseline transfusion risk scores between cohorts. As predicted, the number of units of red blood cells transfused perioperatively correlated with the transfusion risk score (P < .0001). Overall, the 12-hour chest tube drainage volumes and platelet transfusion rates in the prasugrel cohort were significantly greater. However, no statistically significant differences were found in the number of red blood cell transfusions, total hemostatic components transfused, or total blood donor exposure. A significantly greater number of platelet units were transfused postoperatively in the prasugrel patients who underwent surgery within 5 days or less after withdrawal of drug. In an analysis adjusted for the predicted risk of mortality, total donor exposure was not associated with increased mortality.
CONCLUSIONS: The use of prasugrel compared with clopidogrel was associated with greater 12-hour chest tube drainage volumes and platelet transfusion rates but without any significant differences in red blood cell transfusions, total hemostatic components transfused, or total blood donor exposure.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995726      PMCID: PMC4151878          DOI: 10.1016/j.jtcvs.2012.07.059

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

1.  Blood transfusion as a quality indicator in cardiac surgery.

Authors:  Aryeh S Shander; Lawrence T Goodnough
Journal:  JAMA       Date:  2010-10-13       Impact factor: 56.272

2.  European system for cardiac operative risk evaluation (EuroSCORE).

Authors:  S A Nashef; F Roques; P Michel; E Gauducheau; S Lemeshow; R Salamon
Journal:  Eur J Cardiothorac Surg       Date:  1999-07       Impact factor: 4.191

3.  2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette K Wenger; R Scott Wright
Journal:  J Am Coll Cardiol       Date:  2011-03-28       Impact factor: 24.094

4.  First publications from the Society of Thoracic Surgeons National Database.

Authors:  R P Anderson
Journal:  Ann Thorac Surg       Date:  1994-01       Impact factor: 4.330

5.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

Authors:  Stephen D Wiviott; Elliott M Antman; C Michael Gibson; Gilles Montalescot; Jeffrey Riesmeyer; Govinda Weerakkody; Kenneth J Winters; Jeffrey W Warmke; Carolyn H McCabe; Eugene Braunwald
Journal:  Am Heart J       Date:  2006-10       Impact factor: 4.749

6.  Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

Authors:  Peter K Smith; Lawrence T Goodnough; Jerrold H Levy; Robert S Poston; Mary A Short; Govinda J Weerakkody; Leroy A Lenarz
Journal:  J Am Coll Cardiol       Date:  2012-05-23       Impact factor: 24.094

7.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

8.  Variation in use of blood transfusion in coronary artery bypass graft surgery.

Authors:  Elliott Bennett-Guerrero; Yue Zhao; Sean M O'Brien; T B Ferguson; Eric D Peterson; James S Gammie; Howard K Song
Journal:  JAMA       Date:  2010-10-13       Impact factor: 56.272

9.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

10.  A model for predicting transfusion after coronary artery bypass grafting.

Authors:  J A Magovern; T Sakert; D H Benckart; J A Burkholder; G A Liebler; G J Magovern; G J Magovern
Journal:  Ann Thorac Surg       Date:  1996-01       Impact factor: 4.330

  10 in total
  3 in total

Review 1.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

Review 2.  Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials.

Authors:  Subodh Verma; Shaun G Goodman; Shamir R Mehta; David A Latter; Marc Ruel; Milan Gupta; Bobby Yanagawa; Mohammed Al-Omran; Nandini Gupta; Hwee Teoh; Jan O Friedrich
Journal:  BMC Surg       Date:  2015-10-14       Impact factor: 2.102

Review 3.  Perioperative management and monitoring of antiplatelet agents: a focused review on aspirin and P2Y12 inhibitors.

Authors:  Michael A Mazzeffi; Khang Lee; Bradley Taylor; Kenichi A Tanaka
Journal:  Korean J Anesthesiol       Date:  2017-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.